# Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma

Source: https://onco.cc/trials/nct02887040/  
OnCo record `nct02887040` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Antineoplastons in Glioma & glioblastoma, run by Burzynski Research Institute, not yet recruiting.

## Summary

Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma is a phase 3 interventional study registered as NCT02887040 by Burzynski Research Institute, with 92 participants planned, started 2025-10-01 and due to reach its primary completion in 2026-06. Interventions recorded: Radiation, Atengenal, Astugenal. Conditions recorded: Brain Stem Glioma.

Linked to the technology Antineoplastons because the registry's title names it ("antineoplastons") and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02887040
- Phase: 3
- Setting: A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma
- Sponsor: Burzynski Research Institute
- Enrolled: 92

## Sources

- ClinicalTrials.gov NCT02887040: https://clinicaltrials.gov/study/NCT02887040

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- technologies: [Antineoplastons (Burzynski clinic)](https://onco.cc/technologies/antineoplastons/)

---
JSON: https://onco.cc/api/v1/entities/nct02887040.json